Valsartan is NOT inherently "better" than losartan—the evidence shows they are largely equivalent when used at appropriate doses
The critical issue is dosing, not drug selection. Losartan at 50 mg daily (the commonly prescribed dose) has consistently failed to demonstrate non-inferiority to ACE inhibitors in heart failure trials, while losartan 150 mg daily shows comparable efficacy to other ARBs 1, 2. The problem is that losartan 150 mg daily—the evidence-based dose for heart failure—is higher than the FDA-approved dose for any cardiovascular indication in the US 3.
Key Evidence from Heart Failure Trials
Valsartan demonstrated non-inferiority to captopril in the VALIANT trial (14,703 post-MI patients with heart failure or LV dysfunction), while losartan 50 mg daily failed to demonstrate non-inferiority in the comparable OPTIMAAL trial 1, 2. This difference disappears when losartan is used at 150 mg daily.
The HEAAL trial definitively showed that losartan 150 mg daily was superior to 50 mg daily, with a 10% relative risk reduction in death or heart failure hospitalization (P=0.027) over 4.7 years 1, 2. This mirrors findings from the ATLAS trial with lisinopril, confirming that higher doses of renin-angiotensin system blockers provide greater benefit 1.
Comparative Efficacy Data
Heart Failure Outcomes:
- Val-HeFT trial (valsartan up to 320 mg daily): 24% relative risk reduction in HF hospitalization, ARR 3.3%, NNT 30 over 23 months 1, 2
- CHARM-Added (candesartan): 17% relative risk reduction in HF hospitalization, ARR 4.4%, NNT 23 over 41 months 1, 2
- Both trials showed improvements in symptoms, quality of life, and exercise capacity 1, 2
Hypertension Studies:
Small comparative trials show minimal clinically significant differences:
- One study found valsartan produced more LV mass reduction than losartan (though both were effective) 4
- Another found valsartan 160 mg had a higher responder rate (62%) than losartan 100 mg (55%, P=0.02) 5
- A larger equivalence trial found losartan and valsartan similarly effective at reducing blood pressure 6
The Real Clinical Problem: Underdosing
The target dose of valsartan for heart failure is 320 mg daily—far higher than the 40-80 mg typically used for hypertension 3, 7. Similarly, candesartan's target dose is 32 mg daily versus 4-8 mg for hypertension 3. Most physicians are unfamiliar with these evidence-based doses and mistakenly believe medium-range doses provide equivalent benefits 3.
Critical pitfall: There is little evidence that the highest tolerated subtarget dose yields survival benefits approximating target doses 3. The dose-response curve does not plateau at medium doses.
Practical Recommendations
For heart failure with reduced ejection fraction:
- If using losartan: titrate to 150 mg daily (though this exceeds US FDA approval for most indications) 1, 2
- If using valsartan: titrate to 320 mg daily 1, 2, 8
- If using candesartan: titrate to 32 mg daily 1, 2
For hypertension alone:
- Either drug is acceptable at standard doses 9, 8
- Losartan uniquely decreases serum uric acid levels 6
For ACE inhibitor intolerance:
- Any ARB at target dose is appropriate 1, 2, 10
- Valsartan and candesartan have the strongest heart failure outcome data 1, 2
Important Caveats
- ARBs are no longer first-choice add-on therapy in patients already on ACE inhibitors and beta-blockers; mineralocorticoid receptor antagonists (MRAs) showed greater mortality reduction in RALES and EMPHASIS-HF 1, 2
- ARB add-on therapy reduced HF hospitalizations but did not reduce all-cause mortality, unlike MRAs 1, 2
- In Val-HeFT, a trend toward negative interaction was observed when ARBs were combined with beta-blockers 7
The bottom line: Valsartan isn't inherently superior—it's simply that valsartan at its evidence-based dose (320 mg) has proven outcomes, while losartan is routinely underdosed at 50-100 mg when 150 mg is needed for equivalent benefit.